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ABSTRACT
CLINICAL NEAR-INFRARED SPECTROSCOPY INSTRUMENTATION: POSTURAL
ORTHOSTATIC TACHYCARDIA SYNDROME STUDIES
by
Parvathi Kadamati
The University of Wisconsin-Milwaukee, 2017
Under the Supervision of Professor Mahsa Ranji
Aims: Postural orthostatic tachycardia syndrome (POTS) is a type of chronic orthostatic
intolerance, annually affecting around 500,000 young Americans. Symptoms of POTS include
lightheadedness and persistent increase in heart rate with upright body posture [1-3]. It requires a
medical diagnosis. Impaired cerebral oxygenation of patients with POTS has been reported [4].
The pathophysiology remains unclear, and research is needed to understand the underlying
conditions that lead to POTS. The aim of this research is to design a medical device called
Cytoximeter and apply it to conduct a study between POTS patients and healthy controls for
objective monitoring and quantitative measurements.
Introduction: A custom build near-infrared spectroscopy (NIRS) device called Cytoximeter was
constructed to monitor the blood oxygenation and the redox behavior of intact tissue’s Cytochrome
C Oxidase (CCO), in clinical and research setting, noninvasively. The presence of hemoglobin
absorption leads to complex algorithm implementation to separate the signals of the hemoglobin
and CCO. Today we have different kinds of oximetry available, which provide information about
the hemoglobin levels. However, the hemoglobin signals can only provide information regarding
the changes of oxygen in the tissue. Monitoring CCO may give us information about the metabolic
status of the tissue and intracellular levels of oxygen [5]. CCO is the final acceptor in the electron
transport chain (ETC) and is an essential part of aerobic or anaerobic metabolism [3, 6]. CCO
reduces by taking electrons in ETC cycle. This enzyme accepts electrons and changes to reduced
ii

state. The custom build optical device is designed to monitors the optical densities of the tissue by
applying Beer-Lamberts law to monitor the change in concentration of these chemicals. This
ability can give the NIRS many applications for research and clinical purposes. POTS is a clinical
application for this device; a study was conducted to monitor the POTS patients and healthy control
subjects to observe the difference in oxygenation levels between these two groups while
undergoing the head up tilt table test.
Methods: I measured and compared the difference in the changes in oxyhemoglobin and
deoxyhemoglobin by applying this Cytoximeter to POTS patients and healthy controls while
undergoing the heads-up tilt. The device uses the optimal source to detector separations to acquire
the CCO signal and change in oxygenation of hemoglobin signals, which uses the six wavelengths
near-infrared spectroscopic design. Validation of the device includes conducting the phantom
studies and employing new experimental protocols. In the clinical setting, the device was applied
to the muscles and brain tissue of the patients with POTS and Epilepsy under the standard care of
neurological examiners.
Results: The results showed significant differences in deoxyhemoglobin, oxygenation change and
blood volume between the control subjects and POTS patients. We found that the arterial system
is less compliant with the inability to receive additional blood volume in POTS patients. Results
of the phantom studies that I conducted showed that the device was able to monitor the real-time
changes in oxygenation of blood and the redox state of CCO.
Conclusion: The custom build Cytoximeter successfully monitored the hemoglobin signal along
with the CCO signal. The device provided an objective means of measuring and physiological
findings in understanding the underlying reasons of POTS. Further work is required to determine
whether the calf muscle activation of POTS patients is comparable to the healthy controls.
iii
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1. Introduction

1

Near-infrared spectroscopy (NIRS) is commonly used to monitor hemodynamic responses
by the measuring of the regional concentration changes of oxyhemoglobin (HbO2) and
deoxyhemoglobin (Hb) using near-infrared light [1, 2, 6]. There is no risk or harm in applying
NIRS to subjects for a long time. NIRS also has a high time-based resolution, portable, and low
cost of equipment. These give NIRS many applications in clinical settings monitoring biological
signals [7]. A variety of hemoglobin-based oximetry devices are available; however, clinicians
currently cannot monitor the metabolic status of the tissue continuously and noninvasively [2, 8].
This research aims to monitor the cytochrome c oxidase (CCO) signal noninvasively by extending
the optical techniques used in NIRS. CCO is an enzyme in the mitochondria which take place in
electron transport chain (ETC) and hence can give information about the tissue metabolism [1, 2,
6]. Light in the NIRS transparency window can easily penetrate deep into tissue and can be utilized
to monitor the changes in the concentration of absorbing chemicals inside the tissue. The challenge
of this work lies in the measuring tiny CCO signal along with a significant value of hemoglobin in
the tissue using NIRS.
Applying this clinical device to diseases like Postural orthostatic tachycardia syndrome
(POTS) patients and Epileptic patients could provide an understanding to the clinicians about
underlying reasons behind these disorders.

1.1 My Contributions
I developed and implemented a second-generation tissue Cytoximeter system based on the
first-generation system developed in Biophotonics Lab. I then applied this method to study the
difference in the change in Oxygenation of blood in POTS affected patients and healthy control
subjects. In the procedure, the first step is to determine whether a healthy control subject has any
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observable differences from the POTS patients. To show whether this Cytoximeter can detect the
difference between POTS patients and healthy individuals. The results of this study between the
POTS patients and healthy controls led to a journal article that is in the process of submission for
publication and three poster presentations. One at the Institute of Electrical and Electronics
Engineers (IEEE) Milwaukee, which was awarded the 3rd place in the graduate category, two in
College of Engineering and Applied Science (CEAS) poster competition in 2016 and 2017.
I have redesigned the hardware of the Cytoximeter and replaced LEDs with LASER diodes
of different wavelengths (705nm, 735nm, 750nm, 785nm, 808nm, and 850nm) and fiber optics
system. The LASERs were employed as they have the tighter bandwidth and gives more collimated
light. A new probe was designed using six different light sources with different wavelengths in the
near-infrared window (650-1000nm). These wavelengths are chosen to be different from the
previous incarnation of the probe as cross-talk between the chemicals was found in the results of
the earlier version. I also introduced a fiber optic system which made the probe more efficient. The
higher the number of wavelengths required for more advanced data processing protocol and
filtering algorithm is needed. By using the new wavelengths and new data processing algorithms,
the latest version of the Cytoximeter system can monitor the CCO along with the change in
oxygenation of blood. In the making of second version Cytoximeter probe, I had to implement
several novel approaches.
In this research project, I used different Computer-aided tools and programming languages.
The device was controlled by a laptop running a LabVIEW program. The Virtual Instrument (VI)
drives the device, displays and records the data in real time. I have designed a new LabVIEW
experimental protocols. I have also made some changes in LabVIEW VI program to run the latest
second version of cytoximeter. The recorded data was post-processed using a MATLAB
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programming. I have made some changes to the MATLAB code, as the new version uses different
wavelengths produced by LASER diodes as a light source. Post processing includes the extraction
and separation of the CCO signal and hemoglobin signals. The graphing of representative signals.
As a validation of my probe, I have created a new experimental protocol using a force plate
apparatus where the amount of force applied by the subject can be measured, and LabVIEW
software can monitor the signal of the hemoglobin and CCO. Based on the previous phantom
approach done by people in Biophotonics lab, I have implemented a similar experiment for
validating the CCO signal for this new version of Cytoximeter. This ability could provide crucial
diagnostic information by giving more information about metabolism than a standard blood
oximetry device. The ability to detect metabolic activity status independent of blood oxygenation
could help to determine different parameters of the disease quantitatively.
Since the study requires human subjects, I was certified by the Institutional Review Board
(IRB). My responsibility includes editing and maintaining the consents, recruiting subjects and
conducting every personal for the experiment. I was approved in the Institutional Animal Care and
Use Committee (IACUC), and I am responsible for the IACUC protocol compliance as well.

1.2 Tissue Optics
The tissue oximetry uses a continuous wave light source incident on the tissue. The incident
light migrates through the tissue. The amount of light and angle of light traveling inside the tissue
entirely depends on the absorbing and scattering coefficients of the tissue. While considering the
path of the incident light, one should assume the light traveling inside the tissue as light particles
called photons. The photons travel through the tissue, and some of them are absorbed, and some
diffuse reflected. An oximeter records change in the absorption along the path of photons through
the tissue from source to detector [9]. These change in absorption are used to calculate
4

concentration by using Beer’s law. The path must be determined to find the depth of penetration
and find the concentrations using Beer’s law. The determination of this path length is discussed in
section 1.3 and its subsections.

1.3 Principles of Near-Infrared Spectroscopy
NIRS utilizes wavelengths in the near-infrared window (650-1000 nm) to determine in vivo
concentrations of chromophores. A useful application of NIRS is to monitor the health and
function of a biological tissue both noninvasively and non-destructively.

1.3.1 Oximetry
In the oximetry, near-infrared light is used to measure the changes in concentrations of
oxyhemoglobin (HbO2) and deoxyhemoglobin (Hb) via the modified Beer-Lambert law. This law
relates the amount of light absorbed to the length of the path that the light travels and the
concentrations of chemicals in the tissue [9]. There are two types of oximeter configurations one
is transmission oximetry and other is reflection oximetry. In reflective configurations, the light
source and detectors are placed on the same side of the tissue and the light that is observed at the
detector has been scattered back from the tissue [10]. In transmission oximeters, the light and
detector are placed on opposite sides of a thin tissue typically a finger or earlobe [12, 21]. In general
oximetry, a source of light is incident on the tissue and this light penetrates inside the tissue
traveling in a phase like absorption and scattering or reflecting the detectors [9]. In both systems,
measurement includes the amount of incident light and detected light at the detector. Both forms
depend upon the Beer-Lambert law to calculate chromophore concentrations. The Beer-Lambert
law is as follows:
ln (

𝐼𝑜 (𝜆)
) = ∑𝐿𝑖 µλ𝑖 𝛥𝐶𝑖
𝐼(𝑡, 𝜆)
5

(1.1)

Where 𝐼(𝑡, 𝜆) is the light observed at the detector, Io(λ) is the expected or incident light at
the detector, µ𝑖 is the absorption coefficient of a given chemical, 𝛥𝐶𝑖 is the change in concentration
of a given chemical and L is the average path length that the photon takes from the source to the
detector. This equation is valid for all wavelengths λ although the absorption coefficients will vary
with wavelength according to the absorption spectra of chemical ‘i’ [11-13].
These wavelengths are selected to give the highest signal to noise ratio (SNR). The
oximeter typically uses wavelengths where the absorption spectra of the two species are very
different [14]. Tissue oximeters often use two different wavelengths to determine the
concentrations of both species of hemoglobin. Occasionally, oximeter uses a 3rd wavelength that
corresponds to a point where the two wavelengths have very similar absorption coefficients [15].
This cross point is known as the isosbestic point and can be used to measure blood volume.
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Figure 1.1 The absorption spectra for oxyhemoglobin (HbO2) and
deoxyhemoglobin (Hb). The window highlighted is the transparency window in
NIRS, which tissue has the lowest absorption and is nearly transparent to light.

Figure 1.1 compares the absorption spectra of Hb and HbO2. When hemoglobin attaches
or detaches from oxygen, it undergoes a small conformational change that causes a slight
difference in absorption spectra.

1.4 Cellular Respiration
Cellular respiration consists a large chain of reactions and metabolic activities that take
place in the cell of the living organisms. The term includes both aerobic and anaerobic respiration,
and the energy is generated during this process with oxygen and without oxygen respectively. If
monitoring oxygen consumption, it is giving the information about the tissue’s aerobic cellular
respiration; it does not include any information about anaerobic cellular metabolism. So,
monitoring Cytochrome c oxidase may provide information on anaerobic metabolism [5, 6, 16].

1.4.1 Hemoglobin
Hemoglobin is the oxygen transport protein in the red blood cells. As it carries oxygen,
hemoglobin is involved in aerobic metabolism. This metabolism requires both oxygen and glucose
to function. The oxygen that fuels the aerobic metabolism is the oxygen molecules that are
separated from HbO2 particles. Once it gives the oxygen molecule, it changes to Hb. By monitoring
changes in oxyhemoglobin and deoxyhemoglobin, the aerobic metabolism can be obtained [5, 16].

1.4.2 Cytochrome C Oxidase
Cytochrome c oxidase (CCO) is transmembrane protein found in mitochondria of the cell.
To understand the CCO NIRS signal, one must know the biochemistry behind it. CCO is the final
acceptor ETC. The mitochondrial ETC mediates several different transfers, in the process
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converting ADP to ATP. The change in ATP/ADP ratio provides usable energy to drive a wide
variety of cellular processes [6, 17].
As the final acceptor, CCO accepts the electrons at the end of ETC. When it does, it changes
to reduced state. Then CCO oxidizes and uses the energy produced to pump the protons across the
cell membrane. This process happens very quickly and slowly compared to ETC process as a
whole. So, monitoring the CCO redox state by expecting more reduced state in metabolic activity
and may give information of anaerobic metabolism [15, 18].

1.5 Cytoximeter
The cytoximeter is designed to obtain both the hemoglobin signal and CCO signal in the
selected region of the tissue. The exact wavelengths must be chosen to estimate the amount of
CCO in the tissue based on the absorption spectrum. Like hemoglobin changes whether associated
or dissociated with an oxygen molecule, CCO undergoes a similar conformational change that
affects its absorption spectra as the molecule reduces or oxidizes [19]. The same method that tracks
the changes in HbO2 and Hb has been extended to monitor CCO by adding additional wavelengths
to the detection device. By using all six wavelengths to find the concentrations of the four
chemicals as noted in the figure. In the previous version of Cytoximeter different wavelengths
were used and in results they found cross-talk between four chemicals- HbO2, Hb, reduced CCO
(cyt red) and Oxidized CCO (cyt ox). So, to negate the cross-talk between these chemicals, a
simulation of the wavelengths in the Infrared region (IR) of the absorption spectra was executed
and new wavelengths were determined. The optimum wavelengths determined were 705nm,
735nm, 750nm, 785nm, 808nm, and 850nm. Figure 1.2 shows the absorption spectra for all four
chemicals monitored in this study.
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Figure 1.2 The absorption spectra of the four chromophores in NIRS region. The
six wavelengths that are used to identify these chemicals are highlighted by black
lines.

CCO will not account for most of the light absorption at any of these wavelengths [15].
Therefore, it is necessary to cancel out the effects of the hemoglobin on absorption before
calculating the amount of cytochrome in the tissue. The following equation allows the extraction
of the concentration of these four parameters:
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𝛥𝑂𝐷705
𝛥𝑂𝐷735
𝛥𝑂𝐷750
𝛥𝑂𝐷785
𝛥𝑂𝐷805
(𝛥𝑂𝐷850 )
µ𝐶𝑦𝑡 𝑜𝑥 (705𝑛𝑚)
µ𝐶𝑦𝑡 𝑜𝑥 (735𝑛𝑚)
µ𝐶𝑦𝑡 𝑜𝑥 (750𝑛𝑚)
=𝐿
µ𝐶𝑦𝑡 𝑜𝑥 (785𝑛𝑚)
µ𝐶𝑦𝑡 𝑜𝑥 (805𝑛𝑚)
(µ𝐶𝑦𝑡 𝑜𝑥 (850𝑛𝑚)

µ𝐶𝑦𝑡 𝑟𝑒𝑑 (705𝑛𝑚)
µ𝐶𝑦𝑡 𝑟𝑒𝑑 (735𝑛𝑚)
µ𝐶𝑦𝑡 𝑟𝑒𝑑 (750𝑛𝑚)
µ𝐶𝑦𝑡 𝑟𝑒𝑑 (785𝑛𝑚)
µ𝐶𝑦𝑡 𝑟𝑒𝑑 (805𝑛𝑚)
µ𝐶𝑦𝑡 𝑟𝑒𝑑 (850𝑛𝑚)

µ𝐻𝑏 (705𝑛𝑚)
µ𝐻𝑏 (735𝑛𝑚)
µ𝐻𝑏 (750𝑛𝑚)
µ𝐻𝑏 (785𝑛𝑚)
µ𝐻𝑏 (805𝑛𝑚)
µ𝐻𝑏 (850𝑛𝑚)

µ𝐻𝑏𝑂2 (705𝑛𝑚)
µ𝐻𝑏𝑂2 (735𝑛𝑚)
𝛥𝐶𝐶𝑦𝑡 𝑜𝑥
µ𝐻𝑏𝑂2 (750𝑛𝑚)
𝛥𝐶𝐶𝑦𝑡 𝑟𝑒𝑑
µ𝐻𝑏𝑂2 (785𝑛𝑚)
𝛥𝐶𝐻𝑏
𝛥𝐶
µ𝐻𝑏𝑂2 (805𝑛𝑚) (
𝐻𝑏𝑂2 )
µ𝐻𝑏𝑂2 (850𝑛𝑚))

(1.2)

This equation is the form of a constrained regression problem. This problem can be solved
by a Penrose pseudo-inverse to each side of the equation to be left with an estimate of the
concentrations of the absorbing species on the right-hand side of the equation. While this method
would work under ideal conditions, in practice there are several numerical problems often arise
from approaching a problem such as this. By considering six wavelengths, a few co-linearity
problems will be introduced into the regression matrix. All these issues were solved in the previous
version of Cytoximeter [13].

1.6 Monte Carlo Simulations
The optimal distance between the source and detector depends on the structure of the tissue;
the wavelengths used and desired depth of penetration. Increasing the source to detector separation
results in greater depth of penetration [20]. But increasing the separation distance decreases the
signal to noise ratio. A Monte Carlo method is applied to choose the optimal source-detector
separation for the geometry of calf muscle oximetry. Monte Carlo is a stochastic process that
models the path of photons through the tissue by repeated simulations [21, 22]. Every single
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photon particle will undergo several scattering events in its propagation path from the incident
point to the detection side as a step path as shown in the fig. 1.3. This step size for single photon
can be determined by equation 1.3,
𝛥𝑠 =

−𝑙𝑛(𝜉) −𝑙𝑛(𝜉)
=
µ𝑡
µ𝑠 + µ𝑎

(1.3)

Where 𝜉 is a random variable between 0 and 1, µ𝑎 is the absorption coefficient, and µ𝑠 is the
scattering coefficient.

Figure 1.3 The path of a single photon particle traveling inside the tissue. After
being scattered multiple times. The photon leaves at the same plane it was injected.
By using Monte Carlo simulation, a computerized program is designed to process millions
of photons while the undergoing absorbing and scattering at multiple layers of simulated tissue.
The simulation was coded in a C++ environment, and image processing is performed with
MATLAB by members in Biophotonics lab. The results of these simulations are displayed below.
The tissue is modeled by 0.3 mm of the dermis, 1 mm of sub-dermis and a semi-infinite layer of
the muscle beyond. Fig. 1.4 and 1.5 show Monte Carlo simulation results of light penetration in
the tissue for 2 cm and 3 cm source to detector separation obtained by simulating the trajectories
11

of 108 photons through the calf and brain tissue. The densest parts of these simulations are graphed
to give a sense of the average penetration of this optical path. The 2 cm source to detector
separation provides a depth of penetration up to 1 cm. The 3 cm source to detector separation gives
a depth of penetration up to 1.5 cm.

Figure 1.4 Monte Carlo simulations for muscle geometry at both 2 cm and 3 cm
source-detector separations. The densest parts of these simulations are shown on
the bottom row to give a sense of the average penetration of these optical paths.

1.7 POTS
Postural orthostatic tachycardia syndrome (POTS) is a syndrome caused by the postural
changes in the body of the patient with POTS. Symptoms of POTS include lightheadedness and
persistent increase in heart rate (> 30 bpm in adults and > 40 bpm in children) with upright body
posture [1-3]. Patients with POTS may experience many other symptoms such as fatigue,
12

sweating, tremor, anxiety, palpitation and exercise intolerance. Recumbency and assuming a
supine position typically improve symptoms; however, these symptoms may lead to a high level
of functional disability [23, 24]. A wide range of medications and treatment strategies are
available, mainly emphasizing volume expansion and exercise [23].
In this study, muscle oxygenation and metabolism of POTS patients were monitored to assess
the effect of the postural change during Head-up tilt table (HUT). HUT is a standard test for
patients with a potential POTS diagnosis to evaluate their response to postural change. During the
HUT, blood pressure and heart rate are measured continuously [25]. However, subjects with an
increase in heart rate that meets the diagnostic criteria for POTS have the same symptoms as those
who do not [26]. Thus, other physiologic abnormalities may be present, such as changes in brain
or muscle perfusion that might be detectable with a device such as NIRS during an absence of
other vital sign changes.

1.8 Epilepsy
Epilepsy may occur due to a genetic disorder or by attained brain injury, like trauma or
stroke. Epileptic seizures have the disorder mostly in childhood neurologic condition and it a
significant public health concern [8, 27]. The seizures cause poor coordination and disturbance of
the different systems in the body and may even disable and interfere with the child’s ability to
learn, can also lead to harmful effects in social and psychological function [14, 28, 29]. When a
seizure occurs, a person has symptoms and experiences like abnormal behavior, symptoms,
sensations, and sometimes even have loss of consciousness.
Epilepsy is treated with medicines, and if it is a severe case it is treated by surgery, devices,
or dietary changes. Epilepsy is a disorder in the nerve cell activity in the brain requires a medical
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diagnosis and constant monitoring. NIRS technology has been used to monitor cerebral
oxygenation and blood flow in children and adults in diverse conditions [30-33].
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2. Instrumentation and Design
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The Cytoximeter was designed to monitor the blood hemoglobin signal along with the CCO
signal. The updated version of the probe has six different LASER sources and four photodetectors.
LASERs were used in this new version as they have the tighter bandwidth and produce the more
collimated output of light. This chapter gives the details of the device’s design and instrumentation
involved.

2.1 Hardware implementation

Figure 2.1 Custom build NIRS Oximetry system consists of control box and probe,
connected to a DAQ box and a laptop to run Lab VIEW software.

Figure 2.1 shows the Cytoximeter schematic setup. The device is custom-made for this
project that has a probe and a controlling box. The probe contains the light sources and detectors
that are used to measure the optical densities of the tissue. The probe was placed upon the surface
of the muscle or skull. The control box contains circuitry for controlling the components like
detectors and turning the LASER diodes on and off in sequence. The DAQ board acquire the data
16

and records on the laptop. The laptop also displayed the results of the CCO and hemoglobin data
in real time.

Figure 2.2 Cytoximeter system consists of DAQ board, control box, computer
LabVIEW software and probe.

2.1.1 Probe
The probe head (figure 2.3) has the source and detectors, which are capable of producing
and detecting six separate wavelengths of light. The light sources are LASER diodes. With
different wavelengths 705, 735, 750, 785, 808 and 850nm (HL7001MG / HL7302MG / LT031MD
/ L785P5 / L808P010 / L850P030, Thorlabs inc., NJ., USA). An optical fiber is attached to each
LASER (figure 2.4), and all these six fibers are presented at the center of the probe head. The
optical fibers are used as the LASER diodes diameter is big and there are assembled in an area
around 3x2 mm. Which make the source to detector separation variable, i.e., a different LASER
to detector distances. So, to center them at a single point on the tissue, optical fibers are the best
choice. The construction of probe head with fiber is shown in figure 2.4. On the detection side,
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four multi-pixel photon counters (MPPC’s) (Hamamatsu, S1133-14, Kyoto, Japan) were used on
either side of the probe. These detectors were organized in two pairs to provide two different depths
of penetration. The first pair of detectors were placed at a source-detector separation of 2 cm. The
second pair of detectors were placed at a distance of 3 cm. As discussed in the previous chapter,
the different source-detector separations produced different depths of penetration of the light.

Figure 2.3 Probe head with four detectors and six different wavelengths LASER
source (705/735/750/785/808 & 850nm)

Figure 2.4 Introducing the fiber optics and Laser diodes. The figure shows the step
by step construct process of the probe head.
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2.1.2 Control Box
The control box which controls the probe head to detector the signal from detectors and to
power the sources. It contains the amplifiers for the signal that comes back from the detectors on
the probe. It also circuitry that drives for LASERs. The control box talks with the DAQ board on
the analog and digital channels of the DAQ board. The LASER’s were turned on and off by
transistors in common emitter mode in the control box circuitry. These transistors were controlled
and driven by the digital output from the DAQ board.

2.2 Software Implementation
The second version Cytoximeter software and implementation as the previous version. This
section will give details for information LabVIEW program that helps to collect and monitor the
data.

2.2.1 LabVIEW
The LabVIEW software operates the controlling parts of the Cytoximeter, like the DAQ
board and circuit box. The software has a virtual instrument (VI) that accepts the analog input
channels from the DAQ board for four detectors. Output a single eight-bit digital number to control
which LASER to on and off based on configuration designed. The complete program was built
with a large number of sub-Vis. Each sub-VI could perform its task and function that was necessary
to the data analysis process. These sub-VIs was accessed through a top-level hub VI that also
controlled the paths and names of the files generated by each sub VI. All of these VIs saves and
store their data in a Technical Data Management Stream (TDMS) file format for post-processing.
The DAQ board was programmed to continuously sample at each of the channels at a fixed
rate. This rate of sampling was obtained based on the maximum response time of the circuitry.
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Similarly, the lights were turned on and off at a variable rate of up to 20Hz. That translates to a
range of samples per wavelength and sampling rate for an entire six wavelengths cycle which can
be changed depending on the results.

2.2.2 Dark Current Correction
The first VI in the series was the dark current correction VI. This VI get the amount of
signal that was due to dark current on each of the channels. Dark current is an issue in every
optoelectronic system which is caused by current leakage of the semiconductors in the detectors
and by parasitic connections between the components in the system. As this process was not
repeated before the experiment, subsequent VIs use the most recently obtained values. This test
was done while the LASER’s were being switched on but the board was placed on a black media.
This sub-VI is run before perform the main sub-VI, as it is essential to run while acquiring
the small signals, as it may make a huge difference. The first VI in the series was the dark current
correction VI. Dark current is a small little voltage that comes in the electronic system even when
there is no light at the detectors. The dark current values were obtained to be stable over a long
time and repeated tests. Therefore, it was assured that small changes in dark current were a minimal
source of error in the system.
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Figure 2.5 Dark current front panel window

2.2.3 Ambient Pollution Correction
To correct the ambient light pollution, a second sub-VI measured light seen by the probe
after it had been applied to the subject. The LASER’s were not switched on during this procedure
so that only the ambient light was recorded during this time. Even though the detectors were
located on the underside of the probe when it was applied to the subject’s skin the detectors were
sensitive enough to get the ambient light around the room with bright lighting. As the probe was
designed for clinical use, it was considered that the lighting conditions in the room would not
always be ideal.

2.2.4 Baseline Acquisition
To obtain optical densities baseline had to be processed and established. Except for the
sources, i.e., LASERs, we do not want any other light affecting the baseline, so the dark current
and ambient light levels which we obtained before baseline get subtracted from the baseline values.
That was done by the baseline sub-VI internally. The baseline measurements were monitored until
they were stable for at least a minute. The third VI obtains the baseline, during at the time where
the LASER is not turned on or doing anything else to acquire the Hemoglobin signal and CCO
signals.
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Figure 2.6 Baseline front panel window

2.2.6 Force Plate Protocol Baseline
In Force plate protocol, subject applies a force which is measured by the strain gauge. So
this strain gauge instrumentation is connected to the LabVIEW software. In this, the subject needs
to apply his/her maximum force at the starting of the experiment. So the LabVIEW software VI is
designed to fix the maximum and then run the baseline VI to acquire the signals. This force plate
baseline begins after the dark current VI. Once the maximum range of force is fixed in the VI, then
baseline VI runs the LASERs and acquires the light levels. According to different protocol design,
the subject may ask to apply certain of force (example 80%, 60% and 40% of max). While the
baseline VI is in the process, when the subject applies certain force, it can record the value of the
force applied.
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Figure 2.7 Force Plate Protocol Baseline

2.2.6 Acquisition VI
The acquisition VI was used for reading the light levels of the light the incident on the
subject body and then it will change or convert them to optical densities. Then it will record and
display the real-time estimates. The OD values are used to estimate the changes in hemoglobin
and CCO values. The baseline VI was the first VI for the experiment. This VI can also perform
the functions by subtracting the dark current and ambient light from the light levels obtained and
then applying the modified Beer-Lambert law to get the signal changes.
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Figure 2.8 Acquisition front panel window

2.2.7 Offline Data Analysis
This code analyzed the information by performing a data analysis technique known as
Kalman filtering, which is discussed and implemented in the previous version [13]. When the
Kalman filtering algorithm was applied and completed, estimates of the trends of HBO2, HB,
Oxidized CCO, and Reduced CCO are obtained. In addition to these four signals, other three
important signals were calculated, and these are blood volume, change in oxygenation (oxy) and
CCO redox state. These equation mentioned below are assumed approximations that give the
general trend of the oxy, CCO Redox State, and Blood volume. The oxy, blood volume, and
redox state were assumed estimations from the following equations.
∆𝑜𝑥𝑦 = 𝛥𝐶𝐻𝑏𝑂2 − 𝛥𝐶𝐻𝑏

(2.1)

∆𝐵𝑉 = 𝛥𝐶𝐻𝑏 + 𝛥𝐶𝐻𝑏𝑂2

(2.2)

∆𝐶𝐶𝑂 𝑅𝑒𝑑𝑜𝑥 𝑆𝑡𝑎𝑡𝑒 = 𝛥𝑅𝑒𝑑𝑢𝑐𝑒𝑑 𝐶𝐶𝑂 − 𝛥𝑂𝑥𝑖𝑑𝑖𝑧𝑒𝑑 𝐶𝐶𝑂

(2.3)

Reasonable expectations of oxy would represent the ratio of HbO2 to whole blood, Blood
Volume would have the total blood in the tissue and redox state would represent the ratio of
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reduced CCO to total CCO. As the device can only detect relative changes of these four chemicals
and not the absolute values, which are impossible. So, the above equations are estimates of those
chemicals. The data is collected and recorded in TDMS file format for post-processing. The TDMS
file will open as excel format on a personal computer where the post analysis of the data is done.
And then analyzed in MATLAB for processing and graphing of these chemicals.

2.3 Research Protocols
To understand and correlate the results of the custom build probe, some research protocols
are employed. These protocols aimed to undergo some exercises. Designed a measuring apparatus
using six-axis strain-gauge.

2.3.1 Strain Gauge
A six-axis strain gauge (Advanced Mechanical Technology, Inc., MC3A-1000, Watertown, MA)
was utilized to measure the force that a subject applied to their foot Fig. 2.8. For the usage, applied
the same settings and amplifier equipment that we used by the previous Biophotonics lab members.

Figure 2.9 The strain gauge, arrows indicate the default coordinate system.

2.3.2 Force Plate Apparatus
A custom-built device was developed to hold the strain gage in all these arrangements.
This device can

be

seen

in

figure

2.9.

The employed

protocol required

the capacity to get the drive that subjects were able to apply by flexing their foot while in
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standing, inclined and

sitting stances.

matter since the device had

to

be

This
able

made
to

the

be utilized in

strain gage a
all

challenging

these arrangements.

The apparatus was built from machined metal parts and lumber. The device also included a
foot restraint that is commercially accessible for utilize in paddling work out machines.

Figure 2.10 The Force plate apparatus, designed to hold the strain gauge which
measure the force applied by the subject.

2.3.3 Pressure Cuff Validation
A different approach, casuing ischemia in the forearm muscle to validate the hemoglobin
signals changes monitored by Cytoximeter. That was based on published research which uses a
charge-coupled device (CCD) based tissue spectroscopy [36]. The same experimental protocol
was applied to an individual to cross-checked the hemoglobin results of the Cytoximeter.
The probe was applied to the forearm muscle, and a pressure cuff is attached to the arm.
By applying pressure rapidly to cause oxygen desaturation in the forearm as shown in the figure
2.11.
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Figure 2.11 Pressure Cuff Protocol

2.4 Phantom Validation
2.4.1 Solid phantom
An artifical tissue called as phantom has two phases i.e., solid and liquid phase. The solid
phantom was made by using 1% by mass agarose-gel [34]. The liquid phase consists of intralipid
as scattering material and India ink as absorbing the material. The ink was used as it has the
absorbing properties which could mimic different tissues [35]. The fat emulsion called intralipid
was added as scattering coefficient to the gel with excellent reliability [34, 35]. Cubbedo reported
on trends on optical properties using these materials. The data from these trends were used to create
several layers of the phantom that resembles different layers of the tissue. The ink has a nonnegligible contribution to scattering of the phantom to develop a more reliable phantom,
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concentration of both Intralipid and India ink were extrapolated from writing that utilized a
phantom that contained both [34, 36], that were used to change the optical properties of the gel.
The concentration of both India ink and Intralipid are added to the phantom based on the
type of tissue. Different types of tissues have a different kind of absorption and scattering
coefficients.
Tissue

Reduced scattering
coefficient (cm−1 )

Concentration of
intralipid

Absorption
Coefficient

Concentration of
India Ink by

(% emulsion)

(cm−1 )

(% by volume)10−5

Dermis

23

3.2

0.02

3.6

Muscle

9.0

1.1

0.05

8.2

Skull

30

4.3

0.02

3.6

Brain

10

1.25

0.05

8.2

Table 2.1: Optical properties of the phantom and simulated tissue.

In the construction of the artificial tissue called phantom, which is made by mixing the
agarose with water and heated in a microwave and then it cools down into a solid clear material.
Then based on the tissue absorption and scattering coefficients India ink and intralipid
concentrations are added as a solution. Thus, a layered solid phantom is made and be shown in the
fig.2.10. a). The second phantom mentioned liquid phantom is made to detect the changes in
concentrations like CCO, blood concentrations. To this liquid phantom, this concentration is added
based on the tissue. So, to monitor this change liquid phantom is made. The phantom was
constructed in a plastic cell culture flask (VWR cell culture flask, Standard Line, 75ml). An
agarose gel layer was embedded on one side of the flask while the remaining volume of the flask
is left empty. The rest of the flask was filled with a DI water, Intralipid and India ink solution that
resembles the deeper tissues optical properties. The two-phase phantom is shown in figure 2.10 b).
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Figure 2.12 a) It is only a Solid phantom which is embedded and dried in the cell
culture flask and stuck to the flask wall. b) Solid phantom filled with the liquid
phase.

2.4.2 Phantom Experiments
The two-phase phantoms were used to test and detect the performance of the probe by
detecting the change in concentration of CCO bolus. Figure 2.13 shows the results of one of the
phantom test conducted. The probe is applied to the phantom and monitored the data by adding
hemoglobin and CCO at different intervals. To monitor the reduction in this chemical’s
concentration, a reducing agent called Sodium Dithionite (Sigma-Aldrich, USA) is added. This
experiment is done in a dark environment. The hemoglobin used was Ferrous hemoglobin from
bovine blood (H2500, Sigma-Aldrich, USA). The cytochrome c oxidize chemical used for this
study was prepared and test by MCW personal. The baseline was monitored without adding any
of CCO or hemoglobin chemicals. In second interval, hemoglobin bolus is added where
oxyhemoglobin signal showed an increase. In third interval, more hemoglobin bolus is added,
oxyhemoglobin signal showed a step increase. Then in the next two interval CCO bolus added,
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oxidized CCO showed rise and reduced CCO showed drop. And then a reduced by a reducing
agent as sodium dithionite and monitored for around 10 minutes. Once the reducing agent came
into action, slowly oxyhemoglobin and oxidized CCO decreased and reduced CCO increased.
These results showed that the Cytoximeter device is able to monitor this chemical concentration
changes.

Figure 2.13 Phantom Results
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3. Clinical Data
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3.1 POTS Experimental Protocol
The NIRS oximetry probe was placed on the right gastrocnemius. A gold standard
Covidien oximetry probe (INVOS 5100B, Covidien/Medtronic, Minneapolis MN, USA) was
placed on the left gastrocnemius to be used as a reference for comparison of the change in
oxygenation measurements Fig 3.2.
The subject is asked to lay on the tilt table, monitored for 10 minutes at 0 angle of the
HUT as a baseline. And subject was taken to an angle of 70 and monitored for 30 minutes, and
as a recovery for 10 minutes subject was reclined to 0 as shown in Fig 3.1.

.
Figure 3.1 The heads-up tilt table protocol, NIRS oximetry probe and Covidien
probe are attached to the gastrocnemius muscle. Monitor at 00 and 700 angles of the
tilt table for 10 minutes and 30 minutes respectively.

32

Figure 3.2 Image of the Tilt Table Protocol

3.1.1 POTS Patients
All the POTS patients were recruited under the approval of Institutional Review Board in
Medical College of Wisconsin and Children’s Hospital of Wisconsin. All data were collected in
Children’s Hospital of Wisconsin, Wauwatosa, WI. As part of this exam, the patients were
subjects to undergo heads up tilt table test. Twelve patients (age 8-18 years) underwent this
protocol and were divided into 6 that completed the protocol who had POTS (rise in HR > 40 bpm
in first 10 minutes) and 6 with syncope, and therefore had an incomplete tilt test and may or may
not have had POTS.
The tilt table setup is shown in figure 3.1. On one leg our probe was placed and on the other
leg, a commercially available oximeter was placed on the calf. The two devices were run in parallel
while the subject underwent a 70◦ tilt for 30 minutes. This test was designed to exacerbate
symptoms that the subjects were experiencing. Because of this condition, n=6 of tests were ended
early because the subjects either fainted or were in too much discomfort to continue. As a result,
n=6 of the subjects’ data were counted in data processing for this experiment.
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Subject
type

POTS
Syncope
Healthy
Controls

Mean
age ±
SD

Gender

Max
HR
first
10’ of
tilt

Max
HR
During
Tilt
(bpm)

Tilt
duration
(mins)

91

123

30

3M, 3F

99

118

10~20

21.1±2.6 2M, 4F

72

85

30

14.1±1.9 1M, 5F
11.1±3

Table 3.1: Subjects details include the health condition type, age, gender and heart
rate before,during and after the tilt.

3.1.1 Healthy Controls
The 6 healthy control data were collected in the University of Wisconsin-Milwaukee.
Healthy control subjects (age 18-24 years) were volunteered to this study. And they were
consented and questioned before the procedure. That they could be on no medications and had no
history of fainting, or lightheadedness with standing in the last year. The difference between the 6
patients who completed the protocol and 6 healthy control subjects is considered.

3.2 Epilepsy Experiment Protocol
All the Epilepsy patients were recruited at Children’s Hospital of Wisconsin; n=4 subjects
were monitored while undergoing a standard of care neurological exam. All these patients were
recorded that they had seizures in last 24 hours. As part of this exam, they were subjected to attach
the NIRS cytoximeter probe to the forehead as shown in the fig 3.3. And in addition to the
cytoximeter, a NIRS probes from Hitachi (ETC 4000 NIRS, Hitachi, USA) were attached to the
back of the head. This Hitachi probe only gives the hemoglobin changes. And this protocol is in
progress of obtaining signals.
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Figure 3.3 Epilepsy protocol, NIRS Cytoximeter is attached at forehead of the
subject and Hitachi NIRS probes are attached at back of the head.
.

3.3 Clinical Data
3.3.1 POTS and Healthy controls Clinical data

Figure 3.4 Results of Tilt table test on healthy subjects n=6, showing hemodynamic
changes.
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3.3.1.1 Validation of device
NIRS oximetry probe monitors the oxygenation change. Along with this NIRS probe, as a
reference a different oximeter which is commercially available device in the market to monitor the
oxygenation change (INVOS 5100B Covidien, USA). Figure 3.5 shows the correlation graph
between the two probe’s oxygenation change. The data is shown for both the healthy controls and
POTS patients at the baseline, 700 tilt and recovery. Regional oxygenation change parameter for
Covidien Oximetry device is ‘percentage’ (%), whereas for NIRS probe device’s oxygenation
change parameter is ‘concentration’(microMolar or M).
During the 70tilt, the data trend is similar for oxygenation change in both Covidien
Oximetry device and NIRS probe device for healthy subjects and POTS patients. The value of R2
closer to 1.0 shows the better fit of the regression line between Covidien probe and custom build
NIRS oximetry probe.

36

Figure 3.5 Regional Oxygenation change correlation graph between Covidien
probe and NIRS oximetry Probe results in POTS and healthy controls subjects
during baseline, tilt at 700 and recovery. R2 on the graphs closer to 1.0 show the
better fit of the regression line.

3.3.1.2 Physiological findings
Figure 3.6 shows average oxy-hemoglobin (ΔCHbO2) and deoxyhemoglobin (ΔCHb) data
collected from the healthy control subjects and patients with POTS. The three segments show the
change in the posture of the subject from 0 (baseline) to 70 (tilt) and back to 0 (recovery).
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Oxy-hemoglobin decreases during the 70 tilt in healthy subjects, and Deoxy-hemoglobin
increases during the same time. For POTS patients, the direction is similar, i.e. increase in deoxyhemoglobin and decrease in Oxy-hemoglobin but the rise in deoxy-hemoglobin concentration in
POTS patients is significantly greater than the rise in healthy subjects Statistics are shown in Fig
3.6.

Figure 3.6 Data comparison between Healthy subjects (non-POTS) and POTS
patients depicts changes in average oxy-hemoglobin (HbO2) and deoxyhemoglobin (Hb) concentrations on changing the position of the tilt table at 00, 700
and 00 for 10 mins, 30 mins and 10 mins respectively.

3.3.1.3 Statistical differences
In Fig. 3.7, the statistical analysis, each bar represents the averages of the oxyhemoglobin,
deoxyhemoglobin, change in oxygenation and blood volume for both groups POTS and healthy
subjects during the 70 tilt.
The Student’s two-tailed t-test (p<0.01) is applied to the values of the signals to test for
significant differences. From the figure, the oxyhemoglobin did not show any difference,
deoxyhemoglobin showed significant difference in POTS patients and healthy controls. Hb levels
showed a significant difference between patient and healthy subjects which has a p-value. The
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observed difference shows that deoxy-hemoglobin is significantly more in patients with POTS
than in healthy controls.
Oxygenation change in patient and healthy controls has shown a significant difference with
p<0.01. The drop of change in oxygenation concentration in POTS patients is significantly greater
than in healthy control subjects. Blood volume changes in patients with POTS is more than healthy
controls.

Figure 3.7 Statistical analyses for hemodynamic changes in healthy subjects and
patients with POTS. Change in average oxy-hemoglobin, hemoglobin, change in
oxygenation (oxygen saturation) and blood volume in control subjects during the
700 tilt. Referring p-value is <0.01.

3.3.2 Epilepsy Clinical data
Ambient light and baseline levels of the light were obtained after the application of the
probe on the head. The results of the commercial Hitachi oximeter probes were used to verify the
measurements made by the cytoximeter probe. Epileptic patients need constant monitoring which
could be done by the cytoximeter device to show the blood oxygenation changes and metabolic
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activity by the redox state of CCO. The process of monitoring is still in process, the results show
the oxyhemoglobin and deoxyhemoglobin along with the CCO redox state. The patient had
epileptic seizures in last 24 hours. The results were monitored when the patient is not having the
seizures.

Figure 3.5 Epilepsy representative monitored raw data

3.4 Research Protocol result
This research protocol was employed in order to show the CCO redox state,
oxyhemoglobin and deoxyhemoglobin changes with the muscular exercise effort.

40

3.4.1 Pressure Cuff Experiment
The results of pressure cuff forearm ischemia experiment are shown in Fig 3.9. A 5 minutes
baseline is obtained and then rapidly pressure applied up to 240 mmHg for about 5 minutes in the
cuff which is attached to the subject. The recovery is done for 5 minutes.
The results showed the same trends as in ischemia results from the publication [37],
increase in deoxyhemoglobin and decrease in oxyhemoglobin where rapid pressurizing caused
ischemia in the forearm muscle. That shows the ability of the probe to detect hemoglobin changes.

Figure 3.6 Pressure Cuff results

3.4.2 Force Plate Experiment
The probe was attached to the calf muscle of the subject. The subjects were asked to place
their foot on the apparatus and raise the heel to apply the force on the strain gauge in force
measuring direction. This exercise was repeated at three intervals by a change in the applied force
80%, 60% and 40% of their respective maximum which was set at starting of the protocol in
LabVIEW software. The results of the cytoximeter data of one of the representative are seen in the
figure.
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The results show that, with an increased metabolic activity of the muscle, the CCO redox
state increases at each level of exercise. The oxyhemoglobin decreases, due to increase in
metabolic activity and consumption of oxygen. This gives an increase in deoxyhemoglobin.
During the rest, the metabolic activity decreases so the trends of oxyhemoglobin,
deoxyhemoglobin and CCO redox state were opposite to the exercise results.

Figure 3.7 The results from a force plate experiment. As the subject apply force
measured by strain gauge at 80%, 60% and 40% exercise levels.
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Figure 3.8 The blood volume and change in oxygenation results of the force plate
at different exercise levels.

Figure 3.11: The decrease of oxygenation and increase in blood volume is shown during
the exercise according to the range of metabolic activity. Thus, from the results, we see what we
expect to see with range of metabolic activity on the 80%, 60% and 40% of maximum exercises.

Conclusion and Discussion
The goal of these experiments was to detect the change in hemoglobin along with the
changes in CCO signal. These results have shown the custom-built device can measure the redox
state of CCO along with changes in hemoglobin. Such device will assess the health of the patients
that need constant monitoring of the metabolic actives and change in oxygenation of the tissue.
The tilt table tests demonstrated that the subjects are experiencing venous pooling during
the tilt. The hemodynamic changes observed during the tilt suggests that subjects have experience
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the venous pooling by effective change in their legs blood volume. The remarkable differences in
the pattern of change in HbO2 and Hb may provide a new understanding of the underlying
pathophysiology of POTS. Healthy subjects show a sharp rise in HbO2 that is quickly halted
within the first 2 minutes upright, while POTS patients take about 10 minutes to rise to the same
level. Thus, the slope of rising of HbO2 differs markedly between the 2 groups.
The force plate exercise has demonstrated that exercise levels effect on the amount of
metabolic actives by redox state of CCO. And the Pressure cuff experiment showed the device
could monitor the hemoglobin changes.
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4. Conclusion and Future Work
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4.1 Conclusion
I have designed the second version of Cytoximeter which has Laser diodes as the source.
This Cytoximeter could successfully monitor the hemoglobin signal along with CCO signal.
Applied the cytoximeter to muscle in different protocols and acquired objective means of results
according to the metabolic activity.
Coming to the clinical setting, the cytoximeter was applied to POTS patient and healthy
controls to obtain the significant difference between POTS affected subjects and controls, as well
as produce new physiological findings. This study investigates the potential use of NIRS
spectroscopy for the quantitative measurement of calf hemodynamics in POTS patients and healthy
controls. The custom-built probe was applied to study the hemodynamics in the calf muscle of
patients suffering from POTS during a change in posture with heads up tilt table. This could
potentially help in determining whether tissue tonicity plays a role in the symptoms experienced
by POTS patients. Such results could be used to quantitatively track the progress of a therapy in
terms of changes in muscle oxygenation. Another application would be in POTS examinations, as
a means of providing objective evidence of the degree of the syndrome. The cytoximeter can be
used as a clinical tool to acquire muscle or brain oximetry data from patients suffering from POTS
and Epileptic seizures. The results of that study showed the ability of NIRS and its applications in
the clinical settings.

4.2 Future Work
In clinical near-infrared spectroscopy (NIRS), movements of the subject often cannot be
controlled. That can cause significant step changes in the baselines measurements of attenuated
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signals [7].
The manual identification and correcting this motion artifact in NIRS data is timeconsuming and may even be useless because it may lose valuable data. Updating the NIRS device
by an automated method for identifying and correcting motion artifacts. An accelerometer-based
motion artifact can provide long term application of NIRS.
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